These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 26471179)
1. Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma. Pan F; Ruan Z; Li J; Pang X; Zhang Y; Zou L; Liang H Med Oncol; 2015 Nov; 32(11):252. PubMed ID: 26471179 [TBL] [Abstract][Full Text] [Related]
2. Lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy increases the survival of patients with high-risk lymph node positive nasopharyngeal carcinoma. Zhang S; Lin S; Hu L J BUON; 2016; 21(1):161-7. PubMed ID: 27061544 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma]. Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223 [TBL] [Abstract][Full Text] [Related]
4. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma]. Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443 [TBL] [Abstract][Full Text] [Related]
5. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma. Zhang L; Shan GP; Li P; Cheng PJ Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000 [TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945 [TBL] [Abstract][Full Text] [Related]
8. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma. Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883 [TBL] [Abstract][Full Text] [Related]
10. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials. Kong L; Zhang Y; Hu C; Guo Y; Lu JJ Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials. Kong L; Hu C; Niu X; Zhang Y; Guo Y; Tham IW; Lu JJ Cancer; 2013 Dec; 119(23):4111-8. PubMed ID: 24037893 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma. Liang Z; Wang S; Lin Z; Feng S; Cheng Z; Yang Y; Kuang Y; Fidelis C; Ullah S; Li F Cancer Chemother Pharmacol; 2016 Mar; 77(3):643-51. PubMed ID: 26831498 [TBL] [Abstract][Full Text] [Related]
14. Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinoma. Wei WH; Cai XY; Xu T; Zhang GY; Wu YF; Feng WN; Lin L; Deng YM; Lu QX; Huang ZL Asian Pac J Cancer Prev; 2012; 13(3):785-9. PubMed ID: 22631648 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653 [TBL] [Abstract][Full Text] [Related]
16. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma. Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908 [TBL] [Abstract][Full Text] [Related]
17. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907 [TBL] [Abstract][Full Text] [Related]
18. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update. Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692 [TBL] [Abstract][Full Text] [Related]
19. Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Du C; Ying H; Zhou J; Hu C; Zhang Y Int J Clin Oncol; 2013 Jun; 18(3):464-71. PubMed ID: 22527846 [TBL] [Abstract][Full Text] [Related]
20. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. Li WF; Li YQ; Chen L; Zhang Y; Guo R; Zhang F; Peng H; Sun Y; Ma J BMC Cancer; 2015 Oct; 15():810. PubMed ID: 26506820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]